Skip to content

Resistant Starch, Antioxidant Status and Insulin Resistance

The Effect of Resistant Starch Supplementation on Antioxidant Status and Insulin Resistance in Overweight and Obese Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01992783
Enrollment
21
Registered
2013-11-25
Start date
2013-08-31
Completion date
Unknown
Last updated
2015-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

Resistant Starch, Antioxidant Status, Insulin Resistance, Overweight, Obesity

Brief summary

The aim of this study is to evaluate whether supplementation with resistant starch improves biomarkers associated with antioxidant status and insulin resistance in subjects with overweight and obesity.

Interventions

DIETARY_SUPPLEMENTHi-maize resistant starch

13.5 g/day

DIETARY_SUPPLEMENTMaltodextrin

13.5 g/day

Sponsors

Urmia University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Overweight and obese adults * Age: 20-50 years

Exclusion criteria

* weight loss or gain (more than10%) over the past 6 months, or weight loss (more than 5%) over the past 1 month * pregnancy, lactation or menopause * History of acute disease or clinical evidence of cancer, acute or chronic inflammatory diseases, cardiovascular disease, renal disease, liver disease, thyroid or endocrine disease * Gastrointestinal disease of which ingredients found in the study products have adverse effects on that * Use of antihypertensive, lipid lowering or glucose lowering medications * Taking antioxidant, vitamin, and/or mineral supplements * smoking

Design outcomes

Primary

MeasureTime frameDescription
Antioxidant status4 weeksSuperoxide dismutase (SOD), Plasma malondialdehyde (MDA), Total antioxidant capacity (TAC)

Secondary

MeasureTime frameDescription
Insulin resistance4 weeksFasting glucose, Fasting insulin, Insulin resistant (HOMA-IR)
Lipid profile4 weeksTriglyceride, Total cholesterol, HDL-cholesterol, LDL-cholesterol, Total cholesterol/HDL-cholesterol
Blood pressure4 weeks
Anthropometric parameters4 weeksHeight, Weight, Body Mass Index (BMI), Waist circumference

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026